Member Info for CHELSEA7

Hi Knowlesi, well buying into the IP and existing managent after completing a high degeree of due diligence is really as much as he could have done to prove to us he is here for the long term.

Do you really think his business know how will be used so sparingly? I don"t but as you say he has more insight than both of us so I will trust his judgement and further to buying in he has of course added to his holding with the 2.950m shares he bought.

I think the only thing we differ on there isI have great hopes for Vulpes involvement and what they can bring to the table. I do think he originally set down his budgets for the research and collaboration timelines, which in effect they have paid for, and knowing how much more will be needed when those funds expire, which will not be so far away, he will one of the first at any table whether it b BioNTech, Avidamab or whoever.. He certainly fitted the profile of what many shareholders felt we needED to liven up ""for our incompetent BOD), LOL.

Strategically it has never been so important as to try and ensure the many platforms are converging in an orderly fuction. I don"t think we have to wait too longer to see how there addition is panning out. and would Scancell have sold 17.33% of the company at 5p and 5.2p if they were not offering the something special the BOD are looking for. ATB

This might help shareholders to decide.....................

https://www.burges-salmon.com/news-and-insight/publications/the-responsibilities-and-duties-of-a-company-director/

In short:

7 duties of a company director
Your company's constitution. The first of these duties is that a director must act within their powers under the company's constitution. ...
Promoting the success of the company. ...
Independent judgement. ...
Exercise reasonable care, skill and diligence. ...
Conflicts of interest and personal benefits.

I do wonder on so many accounts what these Directors could be charged with. Plenty spring to mind.

What took my eye was this part................

Vulpes now owns 16.67% of Scancell and Martin Diggle from Vulpes was appointed to the Scancell board, which we believe will increase the chance of a successful outcome for them. The Scancell share price has risen following the Vulpes investment and our investment has been valued at 6.8p, the AIM share price at 31 August.""

It"s just that I believe that too, many have spoken for years about our lack of business accumen and ability to negotiate deals, perhaps there was and Martin Diggle offers very that to the BOD at least, funny though a few negative posters still beat that drum, I am very surprised.

GN

Just having a trawl around , and in recent weeks a gentleman has been building up his holdings in the company, the share price has been moving up too.

This is what Oxford has to say about us in there Haly Year Report back in September.......................

""Scancell, the Company’s only quoted investment, continues to make progress. It has received approval to start the UK Phase 2 melanoma combination trial of SCIB1 and has begun screening potential patients in Nottingham. It has also started the first joint programme on its new AvidiMab anti-glycan antibody technology, having partnered with a large unnamed pharma. AvidiMab antibodies target sugars rather than proteins on the cell surface.
Scancell raised £3.9 million through the issue of new shares at 5p per share, a significant discount to previous placings, to Vulpes Life Science Fund in June. The money will support the transition of Modi-1 to the clinic. Vulpes now owns 16.67% of Scancell and Martin Diggle from Vulpes was appointed to the Scancell board, which we believe will increase the chance of a successful outcome for them. The Scancell share price has risen following the Vulpes investment and our investment has been valued at 6.8p, the AIM share price at 31 August.""

Previous reports are noted by them commenting on an ever decreasing SP, and this was very positive comment, I think they have called this well, and are ""hopeful"" of a successful outcome.

Interestingly the Full Year Report is due sometime in March, will be interesting to see how it pans out and whether the Holding RNSs build up, either way they do a very good report on Scancell and up to date at the time.

OXF 3 TECH Share Price: 55.00Bid: 40.00Ask: 70.00Change: 0.00 (0.00%) .........yes a pretty big spread, lol. but......actual spread is 45/60 but rising the last couple of months.

I rather think the next bit of good news will take us up to 10, but that is IMHO........higher lows!!

Unfortunately I come from a generation where it is not habitual to use the internet. A very interesting link I am sure among hundreds of others making links between fitness and cancer. I tend to proportion the rise in cancer rates to better diagnostics, that is just part of the story, I am learning....................

https://www.wcrf-uk.org/dietandcancer/energy-balance-body-fatness?gclid=Cj0KCQiAyp7yBRCwARIsABfQsnSlPeRFwjm-yvRsJhPolvkhEqdHKaFMweHg-tr16SupoxNQ-MwDqLAaAtKxEALw_wcB

Just wanted to add to that and mention chemotherapy. We often read nowadays how much kinder it is becoming, and it is being used more often now to stop tumours spreading, to allow patients to get as fit as possible before surgery some 6 months later.

Would like to link that to an article, but I haven"t seen one, just something I have seen firstb hand with a friend and heard from three different cancer patients. Think I will research that a bit this weekend and find some articles on the very subject.

Tremendous man, seen many video interviews with him, and very relevant to us.......................

""Allison’s drug wasn’t the first or only form of immunotherapy; scientists have worked on anticancer vaccines, for example, for decades. What made Allison’s “immune checkpoint therapy” unique was that it used antibodies to unlock the immune system’s potential to kill cancer cells.""

As Ray suggests the immune system will probably teach us a lot in the years to come, and I found Lochanger Lasses post very interesting yesterday discussing how much her fathers fitness regime added many years to his survival. It has only been the last couple of years that I have learnt to be very aware of the importance of diet, fitness and being as kind to our bodies as we can, and it is great te see the NHS now putting cancer patients on fitness regimes before serious treatments and surgery to help ensure survival is the ultimate winner.

Kind of Ray I bought 2 lots of £1500 in the low 5"s to trade, and did so with a 40% rise on one 50% other, around and over 7,52p (£1200 profit), kept my core holding and looking to buy 15% trading pot, to rinse and repeat. Cost of purchases down, average up, and a nice feeling banking profit.

So a stratagy change I guess, not bothered the bid rose higher, I got my margin target. Hardly reinventing the wheel, lol, but quite happy not to replace trading pot and go straight to £8!!!!

Dec 16th............5/5.50
Dec 23rd............6.50/6.80
Dec 30th............7/7.30
Jan 6th............6.7/7.2
Jan 13th...........6.2/6.5
Jan 20th...........6/6.80
Jan 27th...........7.5/8
Feb 3rd............6.7/7.2
Feb 10th...........6.5/7.10
Feb 17th...........Today 7/7.5

Feb

Buys 30k

Sells 9k

.Pedantic moi?? Can"t see us having to look too far ahead to reach inflection points that will take us into double figures now.

Much to look forward too, none so much as human trials, but , BioNYech, TCRs/Glycans and AVIDAMAB alone have the otential to bring in good commercial deals, have we ever had so much in the pipeline converging on one another at any given time before?? Lets enjoy it guys.

Well we began the week 6.50/7.10 and it looks as if we are ending it 7/7.50. Pretty volatile again given such small volumes as we enter H2 Q1 on Wednesday.

Lochinvar enjoyed our conversation, look forward to many more, lets have some news next week even on a fourth collaboration, i long to see us back in double figures and pretty sure that is not just me.

Val Ju, no need to go back to that buddy........""".I base my judgement on a lot of things, sadly your opinion is not one, as it has been negative from the start?"""

Well i have offered my support to what you guys are trying to achieve, and TBH it is not a case of who was positive or negative, just a case of who tou respect, we don"t all have to agree, but yes I was negative from the start and surprised considering I was right you still disrespect me. Anyway, not going there, hope you all get what you are seeking, that is very hard to do, as we know.

I really do get your point, nterested to see what happens at the end.

Hi Val Ju, you know a lot more what has gone down here than I do, but I think we look at individuals involvent through different ways. Do you remember how I used to day in the years to come we will see exactly what each company owns and for what end.

I take your point but all parties whatever their individual involvement have allowed the current situation to happen, hence they are all responsible, and I do feel in time the whole lot of them will never be able to sit as Officers of any Company to evenbe able to do this again.

Tend to agree with you about Suzy, she is complicit in all BOD decisions, financially they are jointly and severally liable as they are legally and morally

For 30k

Oncimmune and Scancell Present Autoantibodies Data
Tue, 29th Aug 2017 07:00

RNS Number : 0917P
Scancell Holdings Plc
29 August 2017
29 August 2017

Oncimmune and Scancell Present Data on use of Autoantibodies in Predicting Response to SCIB1 Immunotherapy

EarlyCDT® demonstrates potential to predict disease recurrence

Nottingham, UK - 29 August 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, and Scancell Holdings plc, ('Scancell') the developer of novel immunotherapies for the treatment of cancer, today announce the presentation of data on the use of Oncimmune's autoantibody technology to successfully predict disease recurrence in subjects undergoing SCIB1 immunotherapy for malignant melanoma. The data will be presented at the Cambridge Healthtech Institute (CHI) Immuno-Oncology Summit 2017 on August 29 2017.

The collaborative study, which also included a team at the University of Nottingham, developed a method using a panel of seven tumour associated autoantibodies to predict disease recurrence in patients with resected Stage III/IV melanoma treated with Scancell's SCIB1 immunotherapy. Whilst Phase I/II trials with SCIB1 have been highly encouraging, this additional information potentially enables the identification of patients prior to commencement of therapy who are most likely to respond to treatment in future clinical trials with SCIB1.

Geoffrey Hamilton-Fairley, Chief Executive Officer, commented: "This is the first of a number of companion diagnostics programmes we are undertaking, having shown with internal data that by using Oncimmune's autoantibody platform it is possible to differentiate patient responses to a range of cancer treatments. While validation on a larger data set is necessary, these results indicate that in this case it was possible to identify patients who are most likely to respond to Scancell's SC1B1 and thus further demonstrate the potential of our technology in this application."

Dr Richard Goodfellow, CEO of Scancell added: "If this preliminary data is confirmed in a larger clinical study, it has the potential to improve the design of future clinical trials using SCIB1 by selecting patients most likely to positively respond to our novel treatment and thereby increase the chances of a successful outcome."

I wonder if they still feature in our plans??

They had their Half Year Report Wednesday......................https://www.lse.co.uk/rns/ONC/half-year-report-cei3yq8uzzry9t7.html

And they have risen 20% Wednesday, and 20% up today

Share Price: 43.00Bid: 41.00Ask: 45.00Change: 7.00 (19.44%)

They were trading at 150p less than two years ago, it really isn"t just us.

Three years ago my best pal had bladder cancer, he had private insurance, but he was advised to join a private health club who specialised in getting patients fit for surgery. It cost him £1500 and he went for 3 days a week, whilst they treated him with chemotherapy to stop the tumourgrowing into the final layer of skin and then replaced his bladder with a plastic one. Touch wood all went very well and he is still clear.

The point being you mentioned your fathers fitness and diet, and reading a few articles of late that the NHS are adopting the same principles prior to chemo and surgery, to give patients the best chance of a succesful outcome. My pal swears it was the fitness regime that pulled him through, even to attend every other day and keep occupied and have a mission. Good to see the NHS adopting the same.

Thanks, it is very clear you have a passionate interest in the World of Oncology, which is adding much to this BB and frankly is very contageous.